Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Romond et al. (Thu,) studied this question.

www.synapsesocial.com/papers/69d7b52fb843b2be9949075a — DOI: https://doi.org/10.1056/nejmoa052122

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Assessment of Cardiac Dysfunction in a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel, With or Without Trastuzumab As Adjuvant Therapy in Node-Positive, Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: NSABP B-31· 2005 · 805 citations
2. Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/<i>neu</i>Oncogene· 1987 · 11,719 citations
3. Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience· 2002 · 532 citations
4. Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial· 1975 · 2,360 citations
5. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial· 2002 · 1,958 citations